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A basic phospholipase A2 (LmrTX) isoform was isolated from Lachesis muta rhombeata
snake venom and partially characterized. The venom was fractionated by molecular
exclusion chromatography in ammonium bicarbonate buffer followed by reverse-phase
HPLC on a C-5 Discovery Bio Wide column. From liquid chromatography–electrospray
ionization/mass spectrometry, the molecular mass of LmrTX was measured as
14.277.50 Da. The amino acid sequence showed a high degree of homology between PLA2
LmrTX from L. muta rhombeata and other PLA2 from snake venoms, like CB1 and CB2 from
Crotalus durissus terriﬁcus; LmTX-I and LmTX-II from Lachesis muta muta. LmrTX had PLA2
activity in the presence of a synthetic substrate and alkylation of histidine residues
signiﬁcantly inhibited (P < 0.05) the enzymatic activity of LmrTX and its anticoagulant and
antithrombotic activity. In this study, we examined the ability of the LmrTX in altering
thrombus formation in living mouse, using a photochemically induced arterial thrombosis
model. The control animals that did not receive protein injection showed a normal
occlusion time, which was around 57  7.8 min. LmrTX, the PLA2 from L. muta rhombeata
venom, caused a change in the occlusion time to 99  10 min with doses of 7.5 mg/mice.
Additionally, LmrTX showed the anticoagulant activity in vitro and ex vivo and prolonging
the time aggregation in wash platelet induced by ADP and Thrombin.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The bushmaster is the largest venomous snake in the
Americas and the second largest in the world, reaching
3.40 m. Individuals exceeding 2.80 m in length are rare in
Brazil (Souza et al., 2007). The Lachesis accidents statistic
misleads without a context: the 1.6–2.4% of total snakebites
at the national level become 17% in the Amazon (Ramza,
1994) or more than that in highly fragmented andx: þ55 19 3521 6129.
amico).
lsevier OA license.anthropized areas, such as the Atlantic Forest of southern
Bahia (Souza et al., 2007). Much is said about the great
capacity of adult inoculation of the Lachesis, but the
severity of the accident is independent of the size of the
animal (França and Cardoso, 1989), since, unlike what can
be seen in Bothrops, where the size of the animal is the
main prognostic factor of evolution accidents (França and
Cardoso, 1989), even in surface scratches, inoculation
with a single prey and accidents with young animals,
characterized by low volume of the Lachesis venom inoc-
ulated, can still cause early serious and systemic effect
(Souza et al., 2007). This is probably due to the cascade of
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tion, as well as the synergy between the various actions of
the poison, namely: intense local pain, swelling, profuse
bleeding at the site of the bite, diarrhea and abdominal
pain, vomiting, bradycardia, hypotension/profuse sweating,
inability to swallow or painful attempt to do so, dysphagia
and shock (Souza et al., 2007).
Proteins found in snake venom that affect the clotting
factors can be classiﬁed as those who work in coagulation
factors, including activating factor V, factor X activator,
prothrombin activators and enzymes Thrombin-like, anti-
coagulant factors, including proteins that bind to factors IX/
X, protein C activators, inhibitors of thrombin and phos-
pholipase A2, and those that act in ﬁbrinolysis, including
ﬁbrinolytic enzymes and plasminogen activators (Kini,
2005).
So far, ﬁve PLA2 isoenzymes have been isolated from
Lachesis spp. venoms: two acidic (LmPLA2I and LmPLA2II)
from L. muta (Fuly et al., 2003); two basic (LmTX-I and
LmTX-II) from L. muta muta (Damico et al., 2005) and one
(LsPA-1) from Lachesis stenophrys (de Assis et al., 2008).
However, none have been puriﬁed from L. muta rhombeata
and studied in relation to the anticoagulant activity.
In this study, we report for the ﬁrst time, the puriﬁca-
tion, prediction of primary structure, anticoagulant and
antithrombotic activity of the PLA2 from L. muta rhombeata
venom and its relation with its enzymatic activity.
2. Materials and methods
2.1. Venom and reagents
Venom was collected in Serra Grande Center (IBAMA
authorization number 24945-1), Bahia State Brazil, the only
facility in the country totally dedicated to study and pres-
ervation of the Atlantic Bushmaster, L. muta rhombeata
(www.lachesisbrasil.com.br). All chemicals and reagents
were of analytical or sequencing grade.
2.2. Animals
7–8 weeks C57BL6 mice were supplied by the Animal
Services Unit of the State University of Campinas (UNI-
CAMP). Mice were housed at room temperature on a 12 h
light/dark cycle and had free access to food and water. All
procedures were performed according to the general
guidelines proposed by the Brazilian Council for Animal
Experimentation (COBEA) and approved by the university’s
Committee for Ethics in Animal Experimentation (CEEA/
UNICAMP) number 1790-1.
2.3. Venom fractionation
One hundred mg of crude venom of L. muta rhombeata
was dissolved in 1 ml of 0.2 M Ammonium bicarbonate
buffer, pH 8.0. After centrifugation at 5.000 g for 5 min,
the supernatant was loaded onto a Sephadex G75 column
(1.5 cm  90 cm), previously equilibrated with the same
solution, under a ﬂow rate of 12 ml/h. Three ml fractions
were collected. Five mg from selected PLA2 active fraction
(FIII) was dissolved in 200 ml of 0.1% (v/v) triﬂuoroaceticacid (solvent A). The resulting solution was clariﬁed by
centrifugation and the supernatant was further submitted
to a reversed phase chromatography on a C5 Discovery Bio
Wide Pore 10 mm (25 cm  4.6 mm). Fractions were eluted
using a linear gradient (0–100%, v/v) of acetonitrile (solvent
B) at a constant ﬂow rate of 1.0 ml/min over 50min, and the
resulting fractions were manually collected. The elution
proﬁle of both analyses was monitored at 280 nm, and the
collected fractions were lyophilized and conserved at
20 C. The homogeneity of the ﬁnal material was assessed
by mass spectrometry.
2.4. Phospholipase A2 activity
PLA2 activity wasmeasured using the assay described by
Cho and Kezdy (1991) and Holzer and Mackessy (1996)
modiﬁed for 96-well plates (Beghini et al., 2000). The
standard assay mixture contained 200 ml of buffer (10 mM
Tris–HCl, 10 mM CaCl2 and 100 mM NaCl, pH 8.0), 20 ml of
synthetic chromogenic substrate 4-nitro-3-(octanoyloxy)
benzoic acid 3 mM, 20 ml of water, and 20 ml of PLA2 in
a ﬁnal volume of 260 ml. After adding PLA2 isoforms (20 mg),
the mixture was incubated for up to 40 min at 37 C,
absorbance reading at intervals of 10 min. The enzyme
activity, expressed as the initial velocity of the reaction (V0),
was calculated based on the increase of absorbance after
20 min.
2.5. Determination of the molecular mass of the puriﬁed
protein by mass spectrometry
An aliquot (4.5 ml) of the protein was inject by C18
(100 mm  100 mm) RP-UPLC (nanoAcquity UPLC, Waters)
coupled with nano-electrospray tandem mass spectrom-
etry on a Q-Tof Ultima API mass spectrometer (MicroMass/
Waters) at a ﬂow rate of 600 nl/min. The gradient was 0–
50% acetonitrile in 0.1% formic acid over 45 min. The
instrument was operated in MS continuum mode and the
data acquisitionwas fromm/z 100–3000 at a scan rate of 1 s
and an interscan delay of 0.1 s. The spectra were accumu-
lated over about 300 scans, and the multiple charged data
produced by the mass spectrometer on the m/z scale were
converted to the mass (molecular weight) scale using
Maximum Entropy-based software (1) supplied with the
Masslynx 4.1 software package. The processing parameters
were: output mass range 6000–20,000 Da at a ‘resolution’
of 0.1 Da/channel; the simulated isotope patternmodel was
used with the spectrum blur width parameter set to 0.2 Da,
the minimum intensity ratios between successive peaks
were 20% (left and right). The deconvoluted spectrum was
then smoothed (2  3 channels, Savitzky Golay smooth)
and the centroid mass values were obtained using 80% of
the peak top and a minimum peak width at half height of 4
channels.
2.6. Analysis of tryptic digests
The proteinwas reduced (DTT 5mM for 25min at 56 C)
and alkylated (Iodoacetamide 14 mM for 30 min) prior to
the addition of trypsin (Promega-Sequence Grade Modi-
ﬁed). After the trypsin addition (20 ng/ml in ambic 0.05 M),
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reaction, formic acid 0.4% was added and the sample
centrifuged at 2500 rpm for 10 min. The pellet was dis-
carded and the supernatant dried in a speed vac. The
resulting peptides were separated by C18
(100 mm  100 mm) RP-UPLC (nanoAcquity UPLC, Waters)
coupled with nano-electrospray tandem mass spectrom-
etry on a Q-Tof Ultima API mass spectrometer (MicroMass/
Waters) at a ﬂow rate of 600 nl/min. The gradient used was
0–90% acetonitrile in 0.1% formic acid over 20 min. Before
performing a tandem mass spectrum, an ESI/MS mass
spectrum (TOF MS mode) was acquired for each HPLC
fraction over the mass range of 100–2000 m/z, in order to
select the ion of interest,where these ions were subse-
quently fragmented in the collision cell (TOFMS/MSmode).
Raw data ﬁles from LC–MS/MS runs were processed
using MassLynx 4.1 SCN662 software package (Waters) and
analyzed using the Mascot Distiller v.2.3.2.0, 2009 (Matrix
Science, Boston, MA) with SNAKES database (snake-
s_jun2011 was downloaded from NCBI Taxonomy) release
from June 2011 (http://www.ncbi.nlm.nih.gov/protein/?
term¼txid8570[Organism:exp]), using the following
parameters: peptide mass tolerance of 0.1 Da, fragment
mass tolerance of 0.1 Da, oxidation as variable modiﬁca-
tions in methionine and trypsin as enzyme.
2.7. Amino acid analysis
Amino acid analysis was performed on a Pico-Tag
Analyzer (Waters Systems) as described by Henrikson and
Meredith (1984). LmrTX PLA2, sample (30 mg) was hydro-
lyzed at 105 C for 24 h, in 6 M HCl (Pierce sequencing
grade) containing 1% phenol (w/v). The hydrolysates were
reacted with 20 ml of derivatization solution (ethanol:-
triethylamine:water:phenylisothiocyanate, 7:1:1:1, v/v) for
1 h at room temperature, after which the PTC-amino acids
were identiﬁed and quantiﬁed by HPLC, by comparing their
retention times and peak areas with those from a standard
amino acid mixture.
2.8. Modiﬁcation with p-bromophenacyl bromide
Modiﬁcation of histidine residues was carried out as
previously described by Diaz-Oreiro and Gutiérrez (1997).
Brieﬂy, approximately 3 mg of Lmr-TX were dissolved in
1 ml of 0.1 M Tris-HCI buffer, pH 8.0, containing 0.7 mM
EDTA before adding 125 ml of p-bromophenacyl bromide
(pBPB) solution (1.5 mg/ml in ethanol). The mixture was
incubated for 24 h and the excess reagent was removed by
ultraﬁltration using an AMICON Ultra-15 centrifugal ﬁlter
unit (3000 NMWL), followed by lyophilization.
2.9. Photochemically induction of thrombus formation
7–8 weeks old C57BL6 mice were anesthetized with
xylazine (2%–16 mg/kg) and ketamine (10%–100 mg/kg)
injected intramuscularly and placed in the supine position.
Following a midline cervical incision, the right common
carotid artery was isolated and a Doppler ﬂow probe
(model 0.5 VB; Transonic Systems, Ithaca, NY) was applied.
A 1.5-mW, 540-nm laser beam (Melles Griot, Carlsbad, CA)was applied to the artery from a distance of 6 cm. PLA2 was
injected through lateral tail vein (3.75, 7.5 and 15 mg/
animal) and after 10 min injury was initiated by injection
into the lateral tail vein of rose bengal (50 mg/kg body
weight; Fisher Scientiﬁc, Fair Lawn, NJ) dissolved in
phosphate-buffered saline (PBS). Blood ﬂow was moni-
tored until complete and stable (5 min) occlusion occurred
(Werneck et al., 2008).2.10. Activated Partial Thromboplastin Time (APTT) and
prothrombin time (PT)
Citrated Mouse plasma was obtained after blood was
withdrawn from cava vein in citrate 3.2% and centrifuged at
3000 rpm for 15 min at 25 C. For APTT a 50 ml aliquot
plasma was warmed to 37 C for 2 min, 50 ml APTT reagent
was added and after a 2 min incubation at 37 C, 0.25 M
CaCl2 was added and the clotting time was determined. For
the PT test, 100 ml of CLOT PT reagent was incubated for
4min at 37 C and 50 ml of plasmawas added, triggering the
reaction. These analyses were performed in triplicate, using
the APTT and PT Kit CLOT BIOS diagnosis (CLOT, Brazil) in
a CLOTimer coagulometer. To assay APTT and PT ex vivo,
C57BL6 mice were injected i.v. with LmrTX (15 mg/animal)
and after 5, 15, 30, 60 and 90 min, blood was withdrawn
and processed as described above.2.11. Platelet aggregation assay
C57BL6 mice were injected i.v. with LmrTX (15 mg/
animal). After 1 h mice were anesthetized (xylazine, 2%–
16 mg/kg; ketamine 10%–100 mg/kg) and blood was
collected from cava vein in citrate 3.2%. Whole blood was
centrifuged at room temperature (95 g, for 12 min) to
obtain the platelet-rich plasma (PRP). Five hundred
microliters of platelet-rich plasma (PRP) were added to
700 ml of washing buffer (140mMNaCl, 0.5 mM KCl, 12 mM
trisodium citrate, 10 mM glucose, 12.5 mM saccharose, pH
6) and again centrifuged (800 g, 12 min). Platelets were
gently suspended in Krebs solution containing (mM) 118
NaCl, 25 NaHCO3, 1.2 KH2PO4, 1.7 MgSO4, 5.6 glucose (pH
7.4). Platelet number was adjusted to 1.2  108 platelets/ml
in the presence of 1 mM CaCl2. Platelet aggregation was
performed using an optical aggregometer (Chrono-log,
Kordia Life Sciences, Leiden) at 37 C with 400 ml of washed
platelets placed in glass cuvettes containing a disposable
stir bar for constant stirring. Platelet aggregation was
carried out in ADP (20 mM) and thrombin (0.05 U/mL)-
stimulated platelets.2.12. Statistical analyses
Results were reported as mean  SEM. The signiﬁcance
of differences among means was assessed by analysis of
variance followed by ANOVA test, when several experi-
mental groups were compared with the control group.
Differences were considered statistically signiﬁcant if
p < 0.05.
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Four peaks were obtained after crude venom fraction-
ation on the Sephadex G75 gel ﬁltration column (Fig. 1A).
All fractions were tested for the presence of PLA2 activity.
Peak 3 (FIII) displayed high PLA2 activity. The proteins
contained in this chromatographic peak were further
puriﬁed using reverse phase-HPLC performed on a C5
column (Fig. 1B). All eluted peaks were manually collected,
lyophilized and screened for PLA2 activity. The main frac-
tion, labeled as LmrTX, had PLA2 activity. Analysis by ESI-
MS of the intact protein indicated a molecular mass of
the puriﬁed protein of 14277.50 Da (Fig. 2).
Mass spectrometric analysis was performed in order to
obtain a molecular identiﬁcation and homology study.
Digestion of the protein (LmrTX) with trypsin, followed by
LC/MS/MS, identiﬁed ten peptides. The deduced sequence
and measured masses of alkylated peptides of LmrTX are
summarized in Table 1. The sequence of each peptide was
then submitted separately to the SNAKE database using the
protein search program BLAST-p. Using the position
matches of the ‘de novo’ sequenced peptides with homol-
ogous proteins present in the database, it was possible to
deduce their original position on the unknown protein
LmrTX. Fig. 3 shows the result of BLAST alignment between
LmrTX with the phospholipase A2 from Crotalus durissus
terriﬁcus, L. muta muta and L. stenophrys.
Amino acid analysis revealed the following composition
of LmrTX PLA2: Asx/9, Glx/7, Ser/6, Gly/11, His/2, Arg/9, Thr/
8, Ala/5, Pro/5, Tyr/11, Val/2, Met/2, Cys/14, Ile/5, Leu/6,
Phe/6 and Lys/11. LmrTX showed a high content of Lys and
Arg residues typical of a basic PLA2 protein (data not show).
The enzymatic activity of whole venom, LmrTX PLA2
and alkylated LmrTX (LmrTX (His)), was studied using the
synthetic chromogenic substrate 4-nitro-3-(octanoyloxy)
benzoic acid. The PLA2 activity of L. muta rhombeatawhole
venom, Sephadex G75 fraction (FIII) and LmrTX was
122.70  13.41; 191.65  3.34 and 789.74  6.59 nmol/mg/
min, respectively, as shown in Fig. 4. The alkylation of
histidine residues (with p-bromophenacyl bromide) from
LmrTX, reduced signiﬁcantly the toxin PLA2 activity (onlyFig. 1. (A) Elution proﬁle of L. muta rhombeata venom by molecular exclusion chr
activity. (B) Elution proﬁle of FIII following RP-HPLC on C5 Discovery Bio Wide col
rhombeata venom is indicated.11% of residual activity), 86.47  13.41 nmol/mg/min
(p < 0.05; Fig. 4).
Snake venom phospholipases A2 (PLA2) are an
extremely important and diverse group of proteins that
affects hemostasis. In this study, we examined the ability of
the LmrTX in altering the thrombus formation in living
mouse. For this, we used a photochemically induced arte-
rial thrombosis model in mice. Fig. 5 shows the effect of
LmrTX in thrombus formation in the carotid artery of mice.
Control animals that did not receive the protein injection
showed a normal occlusion time, which was 57  7.8 min.
As shown in Fig. 5, LmrTX, the PLA2 from L. muta rhombeata
venom, caused a change in the normal occlusion time.With
doses of 7.5 and 15 mg/mice, the occlusion time was
99  10 min and 94  11.5 min respectively. The dose of
3.25 mg/mice did not signiﬁcantly differ from control values
(62.6  10 min). The animals that were treated with the
modiﬁed protein showed the occlusion time similar to
control animals (64.4  14.0 min).
Anticoagulant PLA2s (mainly Asp49 PLA2) have been
described in all major snake groups. In in vitro condition,
LmrTX showed anticoagulant activity (APTT), prolonging
the normal clotting time of platelet poor plasma (Fig. 6A).
When mice were pretreated with LmrTX at different times
before determining APTT, the protein showed signiﬁcant
anticoagulant activity with a rapid onset (maximal
response obtained at 15 min pos-injection) which was
sustained during 1 h (Fig. 6B). In the other hand, no
signiﬁcant effect on PT in vitro (Fig. 6C) and ex vivo (Fig. 6D)
was observed.
We also veriﬁed if LmrTX could interfere with platelet
aggregation. The animals that received the protein (15 mg)
showed a partial inhibition in ADP and thrombin-induced
washed platelet aggregation, 43 and 44%, respectively
(Fig. 7).
In snake venom PLA2 enzymes, His48 is conserved and
plays a crucial role in the hydrolysis of phospholipids.
Modiﬁcation of PLA2 enzyme from L. muta rhombeata
venom on His48 residue by alkylation leads to the 89% of
reduction in enzymatic activity, with concomitant loss of
anticoagulant effects in vitro.omatography on a Sephadex G75 column. Fraction III (FIII) contained PLA2
umn. The peak corresponding to the phospholipase A2 (LmrTX) from L. muta
Fig. 2. Molecular mass determination of the native LmrTX PLA2 by nano-electrospray tandem mass spectrometry, using a Q-Tof Ultima API mass spectrometer
(MicroMass/Waters) with output mass range of 6000–20,000 Da at a “resolution” of 0.1 Da/channel.
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Accidents caused by Lachesis venom present many
symptoms like local pain, oedema, haemorrhage and
necrosis at the site of the bite. Moreover, systemic
complications such as nausea, vomiting, diarrhea, hypo-
tension and bradycardia, coagulation disturbances and
renal failure are observed during Lachesis envenomation
(Jorge et al., 1997; Rucavado et al., 1999).
Only a few proteins were puriﬁed from the venom of L.
muta rhombeata, among them a thrombin-like gyroxin
enzyme (Aguiar et al., 1996); a kallikrein-like enzymeTable 1
Measured molecular masses and deduced amino acid sequences obtained
by ESI-QTOF-MS/MS based on the alkylated tryptic peptides of LmrTX
PLA2. The peptides were separated by RP-HPLC and sequenced by mass
spectrometry. C ¼ alkylated cysteine, lysine and arginine residues shown
in bold were deduced on the cleavage and missed cleavage by trypsin. All
molecular masses are reported as monoisotopic.
Position Amoniacid sequence Measured mass (Da)
1–7 HL/IL/IK/QFNK 898,4634
15–33 KNAL/IPFYAFYGCYCGWGGR 2285,9459
43–53 CCFVHDCCYGK 1504,4855
61–69 KWDL/IYPYSLK 1183,5264
70–77 SGYL/ITCGK 884,3910
78–90 GTWCEEK/QL/ICECDR 1741,5744
91–97 VAAECL/IR 817,3577
98–104 RSL/ISTYK 853,4496
105–114 YGYMFYPDSR 1297,4471
115–122 CRGPSETC 965,3567(Giovanni-De-Simone et al., 1997); a b-galactoside binding
lectin (Giovanni-De-Simone et al., 2006) and also the
expression of vascular apoptosis protein (VAP)-like metal-
loprotease from venom gland (Tavares et al., 2008), but
there have been no reports on the puriﬁcation of PLA2 from
this source.
In this paper, we described the puriﬁcation of the ﬁrst
PLA2 from the L. muta rhombeata venom. The isolated
protein, now named L. muta rhombeata toxin (LmrTX), was
able to prolong thrombosis time in a photochemically
induced arterial thrombosis in mice, induced anticoagulant
activity in vitro and ex vivo and reduced platelet aggrega-
tion in the presence of ADP and thrombin. LmrTX was
puriﬁed through an experimental protocol that combined
gel ﬁltration and Reverse-phase HPLC chromatographies.
The protein consists of a single polypeptide chain and
a molecular mass of 14277.50 Da.
PLA2 from L muta rhombeata (LmrTX) shows three
regions that retain a signiﬁcant degree of similarity
between group II PLA2, including the N-terminal region
(forming the hydrophobic channel), the regions of the
active site (formed by H48, D49, Y52 and D89) and binding
of calcium (formed by Y27, G29, G31 and G32). The regions
displaying a lower degree of amino acid homology corre-
spond to structurally less conserved elements, and are
likely determinants of the diverse pharmacology effects
exhibited by venom PLA2s (Arni and Ward, 1996).
The LmrTX sequence returns high homology with the
sequence of a phospholipase A2 present in the venom of C.
durissus terriﬁcus (crotoxin basic chain) (PA2B_CRODU
Fig. 3. Amino acid alignment of the deduced amino acid sequence of the new phospholipase A2 LmrTX with: CB1 (P62022) and CB2 (P24027) from Crotalus
durissus terriﬁcus venom; PLA2A (P86169) from Crotalus durissus ruruima; LmTX-I (P0C942) and LmTX-II (P0C943) from Lachesis muta muta venom and LsPA-1
(P84651) from Lachesis stenophrys. The PLA2 functional domains are show by arrows.
D.C.S. Damico et al. / Toxicon 60 (2012) 773–781778Accession Number P62022) and L. muta muta (LmTX-I and
LmTX-II) (PA2T1_LACMU Accession Number P0C942;
PA2T2_ LACMU Accession number P0C943). It is not
surprising that LmrTX has a high degree of structural
identity with LmTX-I and LmTX-II, since L. muta rhombeata
and L. muta muta are closely related subspecies. Zamudio
and Greene (1997), used mitochondrial genes determi-
nate, that these are, in fact, two subspecies closely related;
especially between L.muta rhombeata and populations of L.Fig. 4. PLA2 activity of L. m. rhombeata venom, Fraction III, LmrTX and
LmrTX(His), modiﬁed on the histidine residues by bromophenacyl bromide,
on the chromogenic substrate 4-nitro-3-octanoyloxybenzoic acid. Error bars
indicate mean plus or minus standard deviation (n ¼ 3 for each group).
*P < 0.05.muta muta from southern regions of its distribution (e.g.
Mato Grosso, Brazil). These authors also point it out that the
speciation process between this two subspecies it is
a recently event (300–800 thousand years ago). Interest-
ingly, it was found that the positively selection evolution
process for the PLA2 family from venoms of Crotalinae
subfamily take, at least 300 thousand years (Gibbs and
Rossiter, 2008). Therefore, the higher degree of structural
identity between these proteins it is an expected
phenomena.
Nevertheless, LmrTX show biochemical and structural
differences with LmTX-I and LmTX-II from L. muta muta
(Damico et al., 2005). As presented in our results LmrTX has
a shorter retention time at similar conditions on HPLC-RP
(21 min) compare with the two PLA2 isoforms (24 min)
puriﬁed from L. muta muta. Also the catalytic activity of
LmrTX (15.79 nmol/min) it is more than twice that showed
by the isoforms LmTX-I and LmTX-II (6.1 nmol/min and
5.7 nmol/min, respectively). Both data clearly indicate that
exits some degree of structural differences between these
proteins.
Along with the biochemical data, the molecular mass of
LmrTX (14,277.50 Da) is different from LmTX-I and LmTX-II
(14,245.4 and 14,186.2, respectively). The molecular mass
difference found is in accordance with the aminoacid
composition, which shown variation in the number of Pro,
Thr and Ala residues.
Despite the biochemical and structural differences
between LmrTX and the isoforms LmTX-I and LmTX-II, the
high degree of identity suggest that this toxin could exert
similar pharmacologic activities, i.e neurotoxic activity
ex vivo.
Fig. 5. Effect of LmrTX on thrombotic occlusion of the carotid artery. (A) Representative blood ﬂow recordings showing the delayed occlusion time and stochastic
ﬂow pattern in treated animals with puriﬁed PLA2. Rose bengal dye was injected at time ¼ 0 min. (B) The time to occlusion of blood ﬂow following injury is
shown. Error bars indicate mean plus or minus standard deviation (n ¼ 5 for each group). *P < 0.05.
Fig. 6. Activated Partial Thromboplastin Time (aPPT) blood test of LmrTX (>) and histidine-alkylated LmrTX (B) on platelet poor plasma. Results are expressed
as a ratio of normal condition test. Error bars indicate mean plus or minus standard deviation (n ¼ 3 for each group).
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Fig. 7. Effect of LmrTX on platelet aggregation. (A) Inhibitory effect of LmrTX on platelet aggregation induced by ADP (20 mM) and Thrombin (0.05 U/mL) in
treated animals with puriﬁed PLA2 (15 mg) (:) or control (C). (B) Representative recordings showing the aggregation curves with agonist alone or LmrTX. Each
point represent the average from ﬁve experiments  SEM. * and ** shown signiﬁcant difference (p < 0.05) compare with the respective control.
D.C.S. Damico et al. / Toxicon 60 (2012) 773–781780Phospholipase enzymes can exert their anticoagulant
effects by the hydrolysis and physical destruction of the
membrane surface required for the formation of coagula-
tion complexes or by their interaction with blood coagu-
lation proteins and not phospholipid hydrolysis (Kini,
2005). APTT is used to measure the integrity of compo-
nents of the intrinsic pathaway and PT measures the
integrity of the extrinsic pathaway. LmrTx interfered only
with APTT, prolonging this time. The protein could be
acting in the enzymatic cleavage of the available phos-
pholipids required to intrinsic pathaway, since it was seen
that chemical modiﬁcation of histidine residues neutral-
ized its anticoagulant activity.
Based on the comparison of the three dimensional
structure of class II PLA2 enzymes, three independent
groups supported the predicted anticoagulant site
(Carredano et al., 1998; Zhao et al., 2000; Singh et al., 2001).
This region shows conformational similarity and the pres-
ence of positively charged residue free for intermolecular
interactions at the corner of molecule corresponding to the
stretch of residues 55–67 seems to be a common feature of
most of the anticoagulant PLA2 enzymes (Carredano et al.,
1998; Zhao et al., 2000; Singh et al., 2001). For the RVV-
VD, a PLA2 from the venom of Russell’s viper (Vipera rus-
seli russeli), a strong anticoagulant PLA2 of this class, this
region has several lysine residues (Carredano et al., 1998).
In LmrTx this region has not been fully determined, only
two residues positively charged in this segment was
showed, which are favorably oriented to induce the anti-
coagulant effect.
When performing chemical modiﬁcation of histidine
residues (alkylation with p-bromophenacyl bromide),
LmrTX showed a reduction in its catalytic activity in 89%
and there was an inactivation of the anticoagulant activity.
The present study supports that anticoagulant activity
in vitro of LmrTX is dependent on its catalytic activity.The same chemical modiﬁcation, when made in PrTX-III
(from Bothrops pirajai) and BthTX-II (from Bothrops jarar-
acussu), two basic Asp49-PLA2s, almost completely inhibi-
ted the catalytic, anticoagulant, myotoxic and cytotoxic
activity (Diaz-Oreiro and Gutiérrez, 1997; Andrião-Escarso
et al., 2000; Soares and Giglio, 2003). These results show
that His48 is essential for the hydrolysis of phospholipids
and that these pharmacological effects are dependent, even
partially, of the catalytic activity (Soares and Giglio, 2003).
A photochemically induced model of arterial throm-
bosis in mice was used to determine the antithrombotic
activity of PLA2 in vivo (LmrTX). The process of thrombosis
after the injection of rose bengal (dye) is related to the
formation of reactive oxygen species from the stimulation
of the dye by laser light, leading to endothelial injury. The
laser remains on until the thrombus formation, and the
blood ﬂow is monitored by an ultrasound probe. When we
compared control animals with animals that received the
LmrTX, the time required to the thrombus formation
(occlusion time ¼ zero blood ﬂow) was extended by
approximately 40 min.
PLA2 enzymes interfere with several physiological
processes, including platelet aggregation. LmrTX produced
a partial inhibition of thrombin and ADP-induced aggre-
gation in washed platelets. PLA2 enzymes can inhibit
platelet aggregation by physical destruction of the integrity
of the platelet membrane via hydrolysis of the membrane
phospholipids, which could affect the functions of recep-
tors that play important roles in platelet aggregation (Kini
and Evans, 1997). As platelet aggregation was performed
with mice washed platelets, probably the mechanism of
action of LmrTx is through its interaction with the platelet
membrane.
The data of the primary structure, together with the
results of the anticoagulant activity (APTT) in vitro and
ex vivo, lead us to infer that this enzyme can be classiﬁed as
D.C.S. Damico et al. / Toxicon 60 (2012) 773–781 781a PLA2 with anticoagulant activity related on its catalytic
activity. In conclusion, the results strongly suggest that
LmrTX exerts its anticoagulant effect thought intrinsic
pathway (interaction with coagulation factors of this way)
or by enzymatically hydrolyzing the plasma phospholipids.
However, further experiment of interaction of LmrTX
with coagulation factors are necessary for better under-
standing of action mechanism of this enzyme in cascade
coagulation.
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